Payment overview · 2025
General Payments
$2,188.09
118 reported records · 19 companies
Healthcare provider profile · identity verified
Marcel E Lechin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLLEGE STATION, TX · NPI 1427000496
Verified facts
What the public records show
CMS Open Payments records show Marcel E Lechin, M.D. received $2,188.09 in general payments during 2025 across 118 reported records.
Abbott Laboratories accounted for 27.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis, Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $607.86 | 27.8% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $458.86 | 21.0% | 26 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $299.80 | 13.7% | 32 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $136.60 | 6.2% | 13 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $115.83 | 5.3% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $98.46 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.70 | 3.7% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.24 | 3.5% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $72.42 | 3.3% | 3 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $39.37 | 1.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.95 | 1.6% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $31.53 | 1.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.50 | 1.3% | 1 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $21.24 | 1.0% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $19.46 | 0.9% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $17.49 | 0.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.29 | 0.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $16.76 | 0.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.73 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,188.09 | 118 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $458.86 | 26 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $458.09 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $299.80 | 32 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $115.83 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $115.29 | 11 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $106.72 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $98.46 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $77.24 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $72.42 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $72.42 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $37.49 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.12 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $35.95 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $35.04 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $31.53 | 1 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOGUARD Normalized: angioguard |
Device | CORDIS US CORP. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| MERLIN@HOME Normalized: merlin home |
Device | Abbott Laboratories | $5.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 395 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
395 | 93 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
148 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
395 | 93 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 454 | 147 |
| Clopidogrel | Clopidogrel Bisulfate | 445 | 145 |
| Amlodipine Besylate | Amlodipine Besylate | 415 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 404 | 120 |
| Eliquis | Apixaban | 395 | 93 |
| Ezetimibe | Ezetimibe | 310 | 102 |
| Carvedilol | Carvedilol | 306 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 262 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 250 | 79 |
| Spironolactone | Spironolactone | 233 | 83 |
| Lisinopril | Lisinopril | 231 | 59 |
| Sotalol | Sotalol Hcl | 214 | 60 |
| Flecainide Acetate | Flecainide Acetate | 200 | 52 |
| Metformin Hcl | Metformin Hcl | 185 | 62 |
| Furosemide | Furosemide | 178 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 155 | 50 |
| Xarelto | Rivaroxaban | 153 | 37 |
| Entresto | Sacubitril/Valsartan | 148 | 34 |
| Repatha Sureclick | Evolocumab | 139 | 26 |
| Potassium Chloride | Potassium Chloride | 135 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 42 |
| Simvastatin | Simvastatin | 117 | 28 |
| Atenolol | Atenolol | 115 | 38 |
| Ranolazine Er | Ranolazine | 107 | 39 |
| Metformin Hcl Er | Metformin Hcl | 94 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 90 | 26 |
| Allopurinol | Allopurinol | 88 | 27 |
| Jardiance | Empagliflozin | 88 | 24 |
| Digoxin | Digoxin | 78 | 27 |
| Farxiga | Dapagliflozin Propanediol | 78 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 27 |
| Valsartan | Valsartan | 77 | 21 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 76 | 26 |
| Glyxambi | Empagliflozin/Linagliptin | 76 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 20 |
| Clonidine Hcl | Clonidine Hcl | 72 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 28 |
| Candesartan Cilexetil | Candesartan Cilexetil | 58 | 17 |
| Dofetilide | Dofetilide | 57 | 12 |
| Multaq | Dronedarone Hcl | 57 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 22 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Vascepa | Icosapent Ethyl | 54 | 16 |
| Gabapentin | Gabapentin | 50 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 15 |
| Telmisartan | Telmisartan | 49 | 14 |
| Nitroglycerin | Nitroglycerin | 46 | 31 |
| Icosapent Ethyl | Icosapent Ethyl | 44 | 16 |
| Glimepiride | Glimepiride | 43 | 16 |
| Omeprazole | Omeprazole | 39 | 13 |
| Ozempic | Semaglutide | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | 13 |
| Eplerenone | Eplerenone | 37 | 11 |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 11 |
| Edarbi | Azilsartan Medoxomil | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Camzyos | Mavacamten | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,188.09 · 118 records | Abbott Laboratories | ANGIOGUARD, ASSURITY, AVEIR, BodyGuardian, CAMZYOS, CARDIVA VASCADE MVP XL VVCS 10-12F, ELIQUIS, Flexitouch Plus, GALLANT, JARDIANCE, Kerendia, LEQVIO, LODOCO, LUTONIX Drug Coated Balloon, LifeVest, MERLIN@HOME, NEXLETOL, Nimbl, ONPATTRO, OPSUMIT, Ozempic, REPATHA, RotarexS 6 F x 135 cm, Rybelsus, UPTRAVI, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error